TY - JOUR
T1 - Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment
T2 - Analysis of 5552 patients from 12 cohorts
AU - Mangia, Alessandra
AU - Milligan, Scott
AU - Khalili, Mandana
AU - Fagiuoli, Stefano
AU - Shafran, Stephen D.
AU - Carrat, Fabrice
AU - Ouzan, Denis
AU - Papatheodoridis, George
AU - Ramji, Alnoor
AU - Borgia, Sergio M.
AU - Wedemeyer, Heiner
AU - Losappio, Ruggero
AU - Pérez-Hernandez, Francisco
AU - Wick, Nicole
AU - Brown, Robert S.
AU - Lampertico, Pietro
AU - Doucette, Karen
AU - Ntalla, Ioanna
AU - Ramroth, Heribert
AU - Mertens, Michael
AU - Vanstraelen, Kim
AU - Turnes, Juan
PY - 2020
Y1 - 2020
N2 - Background and aims: Achieving sustained virological response (SVR; cure) in hepatitis C patients using a simple regimen is key to making elimination by 2030 possible. In the largest real-world analysis to date, the effectiveness of pangenotypic, panfibrotic, single-tablet, sofosbuvir/velpatasvir (SOF/VEL) once-daily for 12 weeks was assessed in 12 clinical real-world cohorts from various geographical areas, settings and treatment practices. Factors affecting risk of not achieving SVR were assessed. Methods: Adults treated with SOF/VEL 400/100 mg, without ribavirin, were included. All HCV patients reaching Week 12 or 24 post-treatment were assessed for SVR12/24. Factors associated with not achieving SVR12/24 for virological reasons were evaluated using logistic regression analysis. Results: Overall, 5552 patients were included: 13.3% treatment-experienced; 20.7% compensated cirrhotic; 30.2% genotype 1; 29.5% genotype 2; 32.9% genotype 3; 4.7% genotype 4; 3.7% HIV coinfection; 13.4% current/former intravenous drug use. Of the 5196 patients evaluated for effectiveness, 98.9% achieved SVR12/24. High SVR12/24 rates occurred in all genotypes including genotype 3 (98.3%; 1649/1677) and in those with compensated cirrhosis (97.9; 1055/1078). Only 55 patients did not achieve SVR12/24 due to a virological reason; the only factor statistically significantly associated with an increased risk of not achieving SVR12/24 was compensated cirrhosis (P =.002). Overall, 6% (332/5552) of patients did not achieve SVR12/24 for non-virological reasons (67% lost to follow-up; 26.5% early treatment discontinuation). Conclusions: In this large cohort, representative of clinical practice, a simple 12-week regimen of SOF/VEL without ribavirin resulted in high SVR12/24 rates in diverse patient populations, even among those with compensated cirrhosis.
AB - Background and aims: Achieving sustained virological response (SVR; cure) in hepatitis C patients using a simple regimen is key to making elimination by 2030 possible. In the largest real-world analysis to date, the effectiveness of pangenotypic, panfibrotic, single-tablet, sofosbuvir/velpatasvir (SOF/VEL) once-daily for 12 weeks was assessed in 12 clinical real-world cohorts from various geographical areas, settings and treatment practices. Factors affecting risk of not achieving SVR were assessed. Methods: Adults treated with SOF/VEL 400/100 mg, without ribavirin, were included. All HCV patients reaching Week 12 or 24 post-treatment were assessed for SVR12/24. Factors associated with not achieving SVR12/24 for virological reasons were evaluated using logistic regression analysis. Results: Overall, 5552 patients were included: 13.3% treatment-experienced; 20.7% compensated cirrhotic; 30.2% genotype 1; 29.5% genotype 2; 32.9% genotype 3; 4.7% genotype 4; 3.7% HIV coinfection; 13.4% current/former intravenous drug use. Of the 5196 patients evaluated for effectiveness, 98.9% achieved SVR12/24. High SVR12/24 rates occurred in all genotypes including genotype 3 (98.3%; 1649/1677) and in those with compensated cirrhosis (97.9; 1055/1078). Only 55 patients did not achieve SVR12/24 due to a virological reason; the only factor statistically significantly associated with an increased risk of not achieving SVR12/24 was compensated cirrhosis (P =.002). Overall, 6% (332/5552) of patients did not achieve SVR12/24 for non-virological reasons (67% lost to follow-up; 26.5% early treatment discontinuation). Conclusions: In this large cohort, representative of clinical practice, a simple 12-week regimen of SOF/VEL without ribavirin resulted in high SVR12/24 rates in diverse patient populations, even among those with compensated cirrhosis.
KW - HCV elimination
KW - Hepatitis C
KW - heterogenous
KW - real-world
KW - sofosbuvir/velpatasvir
KW - sustained virological response
UR - http://www.scopus.com/inward/record.url?scp=85086156547&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086156547&partnerID=8YFLogxK
U2 - 10.1111/liv.14537
DO - 10.1111/liv.14537
M3 - Article
C2 - 32449966
AN - SCOPUS:85086156547
VL - 40
SP - 1841
EP - 1852
JO - Liver International
JF - Liver International
SN - 1478-3223
IS - 8
ER -